First published 9/28/2026, 2:53:15 AM · Last updated 9/28/2026, 2:53:15 AM

Development of an homologous recombination deficiency scoring algorithm for unmatched ovarian tumor sample based on next-generation sequencing

Journal article reports development of a homologous recombination deficiency (HRD) scoring algorithm for unmatched ovarian tumor samples using next-generation sequencing. The supplied record contains only the title, publisher, and publication date and includes no methods, results, validation, or implications.

Categories: science-and-space

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 3/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 6/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 1/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The reported algorithm development may be relevant to ovarian tumor genomics research, but the source record provides no further details.

Sources

Development of an homologous recombination deficiency scoring algorithm for unmatched ovarian tumor sample based on next-generation sequencing

Report an issue